Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to i… Read more
Clal Biotechnology Industries Ltd (CBI) - Net Assets
Latest net assets as of June 2025: ILA32.60 Million ILA
Based on the latest financial reports, Clal Biotechnology Industries Ltd (CBI) has net assets worth ILA32.60 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA52.12 Million) and total liabilities (ILA19.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA32.60 Million |
| % of Total Assets | 62.55% |
| Annual Growth Rate | -5.0% |
| 5-Year Change | -91.01% |
| 10-Year Change | -95.77% |
| Growth Volatility | 65.07 |
Clal Biotechnology Industries Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Clal Biotechnology Industries Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Clal Biotechnology Industries Ltd (2006–2024)
The table below shows the annual net assets of Clal Biotechnology Industries Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA46.16 Million | -61.98% |
| 2023-12-31 | ILA121.41 Million | -16.21% |
| 2022-12-31 | ILA144.90 Million | -57.18% |
| 2021-12-31 | ILA338.37 Million | -34.14% |
| 2020-12-31 | ILA513.79 Million | +3.20% |
| 2019-12-31 | ILA497.85 Million | -42.62% |
| 2018-12-31 | ILA867.62 Million | +7.35% |
| 2017-12-31 | ILA808.20 Million | +7.40% |
| 2016-12-31 | ILA752.50 Million | -31.12% |
| 2015-12-31 | ILA1.09 Billion | -13.24% |
| 2014-12-31 | ILA1.26 Billion | -8.82% |
| 2013-12-31 | ILA1.38 Billion | -1.02% |
| 2012-12-31 | ILA1.40 Billion | +25.86% |
| 2011-12-31 | ILA1.11 Billion | -9.56% |
| 2010-12-31 | ILA1.23 Billion | +56.57% |
| 2009-12-31 | ILA782.91 Million | +185.26% |
| 2008-12-31 | ILA274.45 Million | -11.32% |
| 2007-12-31 | ILA309.49 Million | +166.15% |
| 2006-12-31 | ILA116.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clal Biotechnology Industries Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 139430000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA1.61 Million | 4.40% |
| Other Comprehensive Income | ILA142.63 Million | 389.36% |
| Other Components | ILA1.29 Billion | 3512.37% |
| Total Equity | ILA36.63 Million | 100.00% |
Clal Biotechnology Industries Ltd Competitors by Market Cap
The table below lists competitors of Clal Biotechnology Industries Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZeU Technologies Inc
PINK:ZEUCF
|
$130.79K |
|
Emeis
F:OPA1
|
$130.85K |
|
Clearday Inc
PINK:CLRD
|
$130.87K |
|
KIRIN HOLDINGS - Dusseldorf Stock Exchang
DU:KIR
|
$130.90K |
|
R STAHL N (RSL2.SG)
STU:RSL2
|
$130.77K |
|
PERSIMMON PLC - Dusseldorf Stock Exchang
DU:OHP
|
$130.75K |
|
Sparinvest Globale Fokusaktier KL A
CO:SPIGFA
|
$130.68K |
|
MAIRE TECNIMONT
BE:3OY1
|
$130.57K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clal Biotechnology Industries Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 99,358,000 to 36,633,000, a change of -62,725,000 (-63.1%).
- Net loss of 62,456,000 reduced equity.
- New share issuances of 100,000 increased equity.
- Other comprehensive income decreased equity by 1,121,000.
- Other factors increased equity by 752,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-62.46 Million | -170.49% |
| Share Issuances | ILA100.00K | +0.27% |
| Other Comprehensive Income | ILA-1.12 Million | -3.06% |
| Other Changes | ILA752.00K | +2.05% |
| Total Change | ILA- | -63.13% |
Book Value vs Market Value Analysis
This analysis compares Clal Biotechnology Industries Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 118.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 18.78x to 118.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | ILA1.46 | ILA27.50 | x |
| 2007-12-31 | ILA3.39 | ILA27.50 | x |
| 2008-12-31 | ILA2.91 | ILA27.50 | x |
| 2009-12-31 | ILA5.75 | ILA27.50 | x |
| 2010-12-31 | ILA10.30 | ILA27.50 | x |
| 2011-12-31 | ILA9.90 | ILA27.50 | x |
| 2012-12-31 | ILA8.82 | ILA27.50 | x |
| 2013-12-31 | ILA7.43 | ILA27.50 | x |
| 2014-12-31 | ILA5.20 | ILA27.50 | x |
| 2015-12-31 | ILA4.07 | ILA27.50 | x |
| 2016-12-31 | ILA2.67 | ILA27.50 | x |
| 2017-12-31 | ILA2.56 | ILA27.50 | x |
| 2018-12-31 | ILA2.52 | ILA27.50 | x |
| 2019-12-31 | ILA1.39 | ILA27.50 | x |
| 2020-12-31 | ILA1.90 | ILA27.50 | x |
| 2021-12-31 | ILA1.09 | ILA27.50 | x |
| 2022-12-31 | ILA0.80 | ILA27.50 | x |
| 2023-12-31 | ILA0.63 | ILA27.50 | x |
| 2024-12-31 | ILA0.23 | ILA27.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clal Biotechnology Industries Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -170.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14424.02%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.85x
- Recent ROE (-170.49%) is below the historical average (-27.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -14.64% | -748.88% | 0.02x | 1.22x | ILA-25.99 Million |
| 2007 | -16.25% | -3327.63% | 0.00x | 1.53x | ILA-71.98 Million |
| 2008 | -32.65% | -2609.74% | 0.01x | 1.67x | ILA-108.47 Million |
| 2009 | 12.29% | 1378.82% | 0.01x | 1.76x | ILA12.21 Million |
| 2010 | 35.40% | 9897.55% | 0.00x | 1.38x | ILA251.76 Million |
| 2011 | 8.09% | 963.20% | 0.01x | 1.16x | ILA-20.60 Million |
| 2012 | -9.81% | -1219.58% | 0.00x | 1.83x | ILA-188.95 Million |
| 2013 | -17.50% | -4391.71% | 0.00x | 2.22x | ILA-238.21 Million |
| 2014 | -54.13% | -1538.29% | 0.01x | 2.48x | ILA-435.56 Million |
| 2015 | -21.43% | -466.07% | 0.02x | 2.77x | ILA-173.75 Million |
| 2016 | -58.89% | -884.17% | 0.02x | 3.08x | ILA-250.13 Million |
| 2017 | -7.30% | -64.18% | 0.04x | 2.71x | ILA-66.10 Million |
| 2018 | -11.27% | -352.02% | 0.01x | 2.55x | ILA-84.83 Million |
| 2019 | -68.92% | -136.03% | 0.18x | 2.76x | ILA-176.47 Million |
| 2020 | 35.59% | 52925.73% | 0.00x | 2.00x | ILA78.39 Million |
| 2021 | -51.90% | -39992.41% | 0.00x | 2.58x | ILA-106.84 Million |
| 2022 | -48.99% | -16686.49% | 0.00x | 1.45x | ILA-74.34 Million |
| 2023 | -31.25% | -29856.73% | 0.00x | 1.59x | ILA-40.99 Million |
| 2024 | -170.49% | -14424.02% | 0.01x | 1.85x | ILA-66.12 Million |
Industry Comparison
This section compares Clal Biotechnology Industries Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $35,534,690
- Average return on equity (ROE) among peers: -97.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clal Biotechnology Industries Ltd (CBI) | ILA32.60 Million | -14.64% | 0.60x | $130.78K |
| BioLine RX Ltd (BLRX) | $11.68 Million | -151.01% | 0.71x | $104.99K |
| BioLight Life Sciences Ltd (BOLT) | $60.11 Million | -22.26% | 0.08x | $82.11K |
| Can Fite Biopharma Ltd (CANF) | $13.07 Million | -28.13% | 0.42x | $137.32K |
| DNA Biomed Solns (DNA) | $28.18 Million | -136.72% | 0.30x | $392.94K |
| G.F.C Green Fields Capital Ltd. (GFC-M) | $131.71 Million | 3.17% | 0.24x | $402.34K |
| Matricelf Ltd (MTLF) | $2.80 Million | -153.82% | 1.12x | $388.41K |
| Plantarc Bio Ltd (PLNT) | $1.19 Million | -192.87% | 0.81x | $19.61K |